Resources from the same session
Is a one size fits all approach still appropriate for NSCLS with an EGFR mutation, are all mutations equal?
Presenter: Joachim Aerts
Session: Lilly - Personalising and optimising treatment for metastatic NSCLC patients with EGFR and other co-occurring mutations
Resources:
Webcast
Scientific rationale for dual inhibition of VEGF and EGFR
Presenter: Nobuyuki Takakura
Session: Lilly - Personalising and optimising treatment for metastatic NSCLC patients with EGFR and other co-occurring mutations
Resources:
Webcast
Identifying the clinical and disease characteristics of the high risk patient, what is the science telling us?
Presenter: Federico Cappuzzo
Session: Lilly - Personalising and optimising treatment for metastatic NSCLC patients with EGFR and other co-occurring mutations
Resources:
Webcast